Androgen News and Research RSS Feed - Androgen News and Research

Prostate cancer patients treated with ADT experience mental, emotional well-being during treatment

Prostate cancer patients treated with ADT experience mental, emotional well-being during treatment

​A new study published in the Journal of Urology- reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment. [More]
Prostate cancer vaccines receive a boost in funding

Prostate cancer vaccines receive a boost in funding

The development of two innovative new vaccines that are hoped to offer an alternative to castration therapy for men with recurring prostate cancer, is due for an $8 million boost in funding. [More]
Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS. [More]
Researchers investigate how androgen receptors affect prostate cancer progression

Researchers investigate how androgen receptors affect prostate cancer progression

Approximately 1 out of every 6 American men will be diagnosed with prostate cancer, and this year alone there are expected to be nearly a quarter of a million new cases diagnosed, making prostate cancer the most common malignancy among men in the United States. Center for Nuclear Receptors & Cell Signaling Assistant Professor Daniel Frigo and his research team recently published a study investigating the processes through which androgen receptors affect prostate cancer progression. [More]

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a National Institutes of Health-supported randomized controlled clinical trial. [More]
UCLA researchers discover how prostate cancer stem cells evolve as the disease grows

UCLA researchers discover how prostate cancer stem cells evolve as the disease grows

UCLA researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies. [More]

Breakthrough discovery could lead to development of future therapeutics for prostate cancer

Drs. Andrew Goldstein, Owen Witte, and Tanya Stoyanova and their colleagues from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published online ahead of print in the Proceedings of the National Academy of Sciences. [More]

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an IMRT-based treatment strategy, according to the new study conducted by a group of researchers from T-bingen and Munich in Germany. The target volume concept seems to correctly cover individual pelvic nodes, which is indicated by the absence of any nodal recurrence within five years of follow-up. [More]
Study suggests novel approach for treatment of advanced metastatic prostate cancers

Study suggests novel approach for treatment of advanced metastatic prostate cancers

New study suggests that selective blockade of CRM1-dependent nuclear export represents a completely novel, tumour metastasis-selective approach for the treatment of advanced metastatic prostate cancers. [More]

XTANDI now accepted for use within NHS Scotland for treatment of adult men with mCRPC

The Scottish Medicines Consortium, which advises NHS Scotland on prescribing new treatments, announced today that XTANDI (enzalutamide) is accepted for unrestricted use within NHS Scotland for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy. [More]

Lifestyle changes boost QoL during long-term ADT

A study shows that a lifestyle intervention, involving an exercise program and dietary advice, improves disease-specific quality of life in sedentary men with advanced prostate cancer who are receiving long-term androgen-deprivation therapy. [More]
Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis. [More]

Financial interests ‘driving IMRT uptake for prostate cancer’

A study suggests that the recent rapid uptake of intensity-modulated radiotherapy for prostate cancer in the USA has been driven by urologists with financial conflicts of interest. [More]

IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients

Cancer is a health burden of increasing importance which affects close to 13 million people globally. Bone is often affected in these patients, frequently because of bone metastases, or as a result of anti-cancer therapies which can contribute to bone loss and fragility. [More]

Qigong may help survivors of prostate cancer to combat fatigue

The flowing movements and meditative exercises of the mind-body activity Qigong may help survivors of prostate cancer to combat fatigue. [More]

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada. [More]
Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013. [More]

New approaches needed for testing cancer drugs

Research institutes, regulators and the pharmaceutical industry are urged to cooperate to develop new approaches to testing cancer drugs, in order to bring the revolution in personalised medicine to patients across Europe, says the European Society for Medical Oncology. [More]

Researchers identify existence of precursor cells in early prostate cancers

A team of cancer researchers at the University of California, San Diego has identified the existence of precursor cells in early prostate cancers. These cells are resistant to androgen-deprivation therapy, and may drive the subsequent emergence of recurrent or metastatic prostate cancer. [More]

Long-term hormonal therapy has no additional benefits in men with intermediate-risk prostate cancer

​A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. [More]